Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GenVec has entered into a manufacturing development agreement with Cobra Biomanufacturing for TNFerade, the company's lead product candidate.
Subscribe to our email newsletter
The agreement will cover technology transfer, scale-up, and validation of the manufacturing process for TNFerade through cGMP consistency lots that will be produced at Cobra’s facility in Oxford, UK. GenVec is developing TNFerade for use in combination with radiation and chemotherapy for the treatment of various cancers.
Bryan Butman, senior vice president of Vector Operations at GenVec, said: “Activities under this agreement will establish a clear path for the submission of the chemistry, manufacturing, and controls (CMC) portion of a biological license application for TNFerade as GenVec works towards the completion of our current Phase III clinical trial.”